Previous studies included only a small number of patients with EGFR variations (24, 30); however, these studies did demonstrate that the addition of immunotherapy (atezolizumab or pembrolizumab) significantly improves PFS in patients with genetically altered EGFR in advanced nonsquamous NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.